Apellis Pharmaceuticals Provides Update on Two Phase Ib Trials for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
26 juin 2018 07h30 HE
|
Apellis Pharmaceuticals, Inc.
Severely anemic patients with PNH on treatment with Soliris™ can become transfusion-free with improved hemoglobin when switched to APL-2 monotherapy Treatment-naïve patients with PNH show clinically...
Apellis Pharmaceuticals to Host R&D Day on June 26, 2018
19 juin 2018 08h30 HE
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and CAMBRIDGE, Mass., June 19, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis Pharmaceuticals Reports First Quarter 2018 Business Update and Financial Results
30 avr. 2018 16h00 HE
|
Apellis Pharmaceuticals, Inc.
- APL-2 in Geographic Atrophy (GA) and Paroxysmal Nocturnal Hemoglobinuria (PNH) On Track to Advance into Phase 3 Trials in 2H18 - - Cash Position of $152.9 Million at Quarter-End; April 2018 Public...
Apellis Pharmaceuticals Announces Closing of Offering of Common Stock
23 avr. 2018 18h20 HE
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and WALTHAM, Mass., April 23, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis Pharmaceuticals Announces Pricing of Offering of Common Stock
18 avr. 2018 21h26 HE
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and WALTHAM, Mass., April 18, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis Pharmaceuticals Announces Proposed Offering of Common Stock
16 avr. 2018 17h12 HE
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and WALTHAM, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis Pharmaceuticals Provides Update on Phase 1b Open Label Study of APL-2 in PNH Patients Not Previously Treated with Eculizumab
16 avr. 2018 09h23 HE
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and WALTHAM, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
19 mars 2018 16h30 HE
|
Apellis Pharmaceuticals, Inc.
- Initiation of Phase 3 Programs in Geographic Atrophy (GA) and Paroxysmal Nocturnal Hemoglobinuria (PNH) Planned for 2018; Phase 2 Proof-of-Concept (POC) Data Anticipated in Autoimmune Hemolytic...
Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences
23 févr. 2018 07h00 HE
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and CAMBRIDGE, Mass., Feb. 23, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company developing a platform of novel...
Apellis Pharmaceuticals Announces 18-Month Results of Phase 2 Study (FILLY) of APL-2 in Geographic Atrophy
22 févr. 2018 08h44 HE
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and CAMBRIDGE, Mass., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company developing a platform of novel...